Paul Trippier
Affiliations: | Pharmaceutical Sciences | Texas Tech University Health Sciences Center |
Google:
"Paul Trippier"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Mark G. Moloney | grad student | Oxford | |
| Chris McGuigan | post-doc | Cardiff University | |
| Richard B. Silverman | post-doc | Northwestern (Chemistry Tree) |
Children
Sign in to add trainee| Nihar Kinarivala | grad student | 2013-2017 | Texas Tech University Health Sciences Center (Chemistry Tree) |
| Shirisha Jonnalagadda | post-doc | University of Nebraska Medical Center (Chemistry Tree) |
Collaborators
Sign in to add collaborator| Abraham J. Al-Ahmad | collaborator | 2014- | Texas Tech University Health Sciences Center |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Carmona AV, Jonnalagadda S, Case AM, et al. (2024) Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader. Communications Chemistry. 7: 95 |
| Zhang Y, Sharma S, Jonnalagadda S, et al. (2023) Discovery of the Next Generation of Non-peptidomimetic Neurolysin Activators with High Blood-Brain Barrier Permeability: a Pharmacokinetics Study in Healthy and Stroke Animals. Pharmaceutical Research |
| Huwaimel BI, Jonnalagadda SK, Jonnalagadda S, et al. (2023) Selective carbonic anhydrase IX and XII inhibitors based around a functionalized coumarin scaffold. Drug Development Research |
| Huwaimel BI, Jonnalagadda S, Jonnalagadda S, et al. (2022) Chlorinated benzothiadiazines inhibit angiogenesis through suppression of VEGFR2 phosphorylation. Bioorganic & Medicinal Chemistry. 67: 116805 |
| Jonnalagadda SK, Huwaimel BI, Jonnalagadda S, et al. (2022) Access to Highly Strained Tricyclic Ketals Derived from Coumarins. The Journal of Organic Chemistry. 87: 4476-4482 |
| Rahman MS, Kumari S, Hadi Esfahani S, et al. (2021) Correction to "Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability". Journal of Medicinal Chemistry |
| Rahman MS, Kumari S, Esfahani SH, et al. (2021) Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability. Journal of Medicinal Chemistry |
| Kinarivala N, Morsy A, Patel R, et al. (2020) An iPSC-Derived Neuron Model of CLN3 Disease Facilitates Small Molecule Phenotypic Screening. Acs Pharmacology & Translational Science. 3: 931-947 |
| Maalouf K, Makoukji J, Saab S, et al. (2020) Exogenous Flupirtine as Potential Treatment for CLN3 Disease. Cells. 9 |
| Makoukji J, Saadeh F, Mansour KA, et al. (2018) Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses. Annals of Clinical and Translational Neurology. 5: 1089-1103 |